Telehealth Readiness Assessment of Perinatal Nurses.

OBJECTIVE: To assess telehealth readiness among perinatal nurses in New Jersey. DESIGN: Cohort survey study. SETTING/LOCAL PROBLEM: New Jersey was one of the hardest hit areas in the early months of the COVID-19 pandemic. Telehealth represented an opportunity to provide continuity of perinatal care at a time when health care was significantly disrupted. PARTICIPANTS: Perinatal nurses in New Jersey. INTERVENTION/MEASUREMENTS: The intervention was a five-part, 90-question online survey provided via e-mail invitation to New Jersey State Nursing Association members. Data were collected from June 25 to July 9, 2020. Descriptive statistics, frequency analyses, a Mann-Whitney test on nonparametric measures of groups by age, and a one-tailed t test were completed. Results of the Telehealth Readiness Assessment tool were calculated. Open-text responses were organized and used to illustrate the findings. RESULTS: Fifty-two perinatal nurses responded to the survey. Twenty-two (42%) completed all 90 questions. Partial answers were accepted. Synchronous live telehealth expanded 66% in the wake of COVID-19. Results showed that 37% (n = 15) of participants used telehealth at work, and 27% (n = 11) used it in getting care for themselves or a family member (M = 2.0, SD = 0.86; one-tailed t test, p = .25). In comparing nervousness in using technology with age, scores for those younger than 45 years (Mdn = 3) and those older than 45 years (Mdn = 2) showed no statistically significant difference, U(n<45years = 15, n≥45 years = 17) = 11, z = -0.02, p < .83. Overall, 46% (n = 26) indicated that telehealth could be extremely helpful or very helpful in reducing health care disparities and improving quality. Overall, telehealth readiness was ranked almost ready. CONCLUSION: A telehealth readiness assessment may identify barriers and opportunities that can predict success and failure. Nurses generally accept technology and believe that telehealth could be useful in reducing poor maternal health outcomes and health care disparities.

Increased 1-year continuation of DMPA among women randomized to self-administration: results from a randomized controlled trial at Planned Parenthood.

OBJECTIVES: Self-administration of subcutaneous depot medroxyprogesterone acetate (DMPA-sc) is feasible, acceptable, and effective. Our objective was to compare one-year continuation of DMPA-sc between women randomized to self-administration versus clinic administration. STUDY DESIGN: We randomized 401 females ages 15-44 requesting DMPA at clinics in Texas and New Jersey to self-administration or clinic administration in a 1:1 allocation. Clinic staff taught participants randomized to self-administration to self-inject and observed the first injection; participants received instructions, a sharps container, and three doses for home use. Participants randomized to clinic administration received usual care. All participants received DMPA-sc at no cost and injection reminders via text message or email. We conducted follow-up surveys at six and 12 months. RESULTS: Three hundred thirty-six participants (84%) completed the 12-month survey; 316 completed both follow-up surveys (an 80% response rate excluding eight withdrawals). Participants ranged in age from 16-44. One-year DMPA continuous use was 69% in the self-administration group and 54% in the clinic group (p=.005). There were three self-reported pregnancies during the study period, all occurred in the clinic group; all three women had discontinued DMPA and one reported her pregnancy as intended. Among the self-administration group, 97% reported that self-administration was very or somewhat easy; 87% would recommend self-administration of DMPA-sc to a friend. Among the clinic group, 52% reported interest in self-administration in the future. Satisfaction was similar between groups. No serious adverse events were reported. CONCLUSIONS: DMPA self-administration improves contraceptive continuation and is a feasible and acceptable option for women and adolescents. IMPLICATIONS: Self-administration of subcutaneous DMPA can improve contraceptive access, autonomy, and continuation, and is a feasible and acceptable option for women and adolescents. It should be made widely available as an option for women and adolescents.

Contraception after medication abortion in the United States: results from a cluster randomized trial.

BACKGROUND: Understanding how contraceptive choices and access differ for women having medication abortions compared to aspiration procedures can help to identify priorities for improved patient-centered postabortion contraceptive care. OBJECTIVE: The objective of this study was to investigate the differences in contraceptive counseling, method choices, and use between medication and aspiration abortion patients. STUDY DESIGN: This subanalysis examines data from 643 abortion patients from 17 reproductive health centers in a cluster, randomized trial across the United States. We recruited participants aged 18-25 years who did not desire pregnancy and followed them for 1 year. We measured the effect of a full-staff contraceptive training and abortion type on contraceptive counseling, choice, and use with multivariable regression models, using generalized estimating equations for clustering. We used survival analysis with shared frailty to model actual intrauterine device and subdermal implant initiation over 1 year. RESULTS: Overall, 26% of participants (n = 166) had a medication abortion and 74% (n = 477) had an aspiration abortion at the enrollment visit. Women obtaining medication abortions were as likely as those having aspiration abortions to receive counseling on intrauterine devices or the implant (55%) and on a short-acting hormonal method (79%). The proportions of women choosing to use these methods (29% intrauterine device or implant, 58% short-acting hormonal) were also similar by abortion type. The proportions of women who actually used short-acting hormonal methods (71% medication vs 57% aspiration) and condoms or no method (20% vs 22%) within 3 months were not significantly different by abortion type. However, intrauterine device initiation over a year was significantly lower after the medication than the aspiration abortion (11 per 100 person-years vs 20 per 100 person-years, adjusted hazard ratio, 0.50; 95% confidence interval, 0.28-0.89). Implant initiation rates were low and similar by abortion type (5 per 100 person-years vs 4 per 100 person-years, adjusted hazard ratio, 2.41; 95% confidence interval, 0.88-6.59). In contrast to women choosing short-acting methods, relatively few of those choosing a long-acting method at enrollment, 34% of medication abortion patients and 53% of aspiration abortion patients, had one placed within 3 months. Neither differences in health insurance nor pelvic examination preferences by abortion type accounted for lower intrauterine device use among medication abortion patients. CONCLUSION: Despite similar contraceptive choices, fewer patients receiving medication abortion than aspiration abortion initiated intrauterine devices over 1 year of follow-up. Interventions to help patients receiving medication abortion to successfully return for intrauterine device placement are warranted. New protocols for same-day implant placement may also help patients receiving medication abortion and desiring a long-acting method to receive one.

Adequacy and safety of buccal misoprostol for cervical preparation prior to termination of second-trimester pregnancy.

OBJECTIVE: The objective of this retrospective, descriptive study is to assess the adequacy and safety of buccal misoprostol with and without laminaria for cervical preparation prior to second-trimester abortion. METHODS: We analyzed Planned Parenthood Federation of America data from 2,218 elective dilation and evacuation (D&E) procedures conducted on women at 12 to 23 6/7 weeks of gestation from April 2002 to March 2003. Each woman received 400, 600 or 800 microg of buccal misoprostol with or without laminaria for preprocedural cervical preparation. RESULTS: Of the patients, 62% received 400 mug, 32% received 600 microg and 6% received 800 microg of buccal misoprostol; 42.8% had laminaria inserted for phased cervical preparation. The adequacy of cervical dilation was 88.7%. The D&E procedure was completed during a single surgical procedure for 99.8%. The overall adverse event rate was 19.39 per 1,000 women, with a rate of 4.51 per 1,000 women for serious adverse events. CONCLUSIONS: This descriptive study suggests that use of buccal misoprostol with or without laminaria is effective and safe. If buccal misoprostol eliminates or reduces the need for phased, multiday laminaria 1-3 days prior to the surgical procedure, then its use may offer service advantages such as reduced number of clinic visits and fewer pelvic examinations per woman.